Logo image of NA

NANO LABS LTD-CL A (NA) Stock Fundamental Analysis

NASDAQ:NA - Nasdaq - KYG6391Y1281 - Common Stock - Currency: USD

3.53  -0.18 (-4.85%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to NA. NA was compared to 110 industry peers in the Semiconductors & Semiconductor Equipment industry. NA has a bad profitability rating. Also its financial health evaluation is rather negative. NA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

NA had negative earnings in the past year.
NA Yearly Net Income VS EBIT VS OCF VS FCFNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

NA has a worse Return On Assets (-85.20%) than 94.55% of its industry peers.
The Return On Equity of NA (-789.98%) is worse than 95.45% of its industry peers.
Industry RankSector Rank
ROA -85.2%
ROE -789.98%
ROIC N/A
ROA(3y)-27.64%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NA Yearly ROA, ROE, ROICNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

NA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NA Yearly Profit, Operating, Gross MarginsNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -500 -1K -1.5K

0

2. Health

2.1 Basic Checks

NA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NA has less shares outstanding
NA has a worse debt/assets ratio than last year.
NA Yearly Shares OutstandingNA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M
NA Yearly Total Debt VS Total AssetsNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

NA has an Altman-Z score of -0.66. This is a bad value and indicates that NA is not financially healthy and even has some risk of bankruptcy.
NA has a Altman-Z score of -0.66. This is in the lower half of the industry: NA underperforms 77.27% of its industry peers.
NA has a Debt/Equity ratio of 2.05. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of NA (2.05) is worse than 93.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Altman-Z -0.66
ROIC/WACCN/A
WACC9.67%
NA Yearly LT Debt VS Equity VS FCFNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M -100M -200M -300M

2.3 Liquidity

A Current Ratio of 0.70 indicates that NA may have some problems paying its short term obligations.
With a Current ratio value of 0.70, NA is not doing good in the industry: 94.55% of the companies in the same industry are doing better.
NA has a Quick Ratio of 0.70. This is a bad value and indicates that NA is not financially healthy enough and could expect problems in meeting its short term obligations.
NA has a worse Quick ratio (0.49) than 92.73% of its industry peers.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.49
NA Yearly Current Assets VS Current LiabilitesNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M 800M

2

3. Growth

3.1 Past

NA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1579.31%.
Looking at the last year, NA shows a very negative growth in Revenue. The Revenue has decreased by -92.03% in the last year.
The Revenue has been growing by 232.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1579.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.07%
Revenue 1Y (TTM)-92.03%
Revenue growth 3Y232.71%
Revenue growth 5YN/A
Sales Q2Q%-86.25%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NA Yearly Revenue VS EstimatesNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 200M 400M 600M 800M

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NA Price Earnings VS Forward Price EarningsNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NA Per share dataNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

NA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NANO LABS LTD-CL A

NASDAQ:NA (5/27/2025, 8:00:01 PM)

3.53

-0.18 (-4.85%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)03-25 2025-03-25/bmo
Earnings (Next)09-16 2025-09-16
Inst Owners0.05%
Inst Owner Change-62.72%
Ins Owners5.07%
Ins Owner Change0.01%
Market Cap230.60M
AnalystsN/A
Price TargetN/A
Short Float %1.64%
Short Ratio10.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.18
P/FCF N/A
P/OCF N/A
P/B 51.85
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.17
BVpS0.07
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.2%
ROE -789.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.64%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.49
Altman-Z -0.66
F-ScoreN/A
WACC9.67%
ROIC/WACCN/A
Cap/Depr(3y)1473.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)54.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1579.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.07%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-92.03%
Revenue growth 3Y232.71%
Revenue growth 5YN/A
Sales Q2Q%-86.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1360.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.45%
OCF growth 3YN/A
OCF growth 5YN/A